Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...

This is the final call for entries to the 2025 Cambridge Independent Business Awards. Entry is free online at - but hurry, ...

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with ...

Cambridge UK Pharma giant AstraZeneca is proving a variation on the proverbial enigma as it ponders the most appreciative ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken ...

AstraZeneca’s chief executive has discussed quitting Britain in a move that would deal a significant blow to the City of ...